Drugs / recombinant interferon alpha-2a
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00873236 | Apr 2008 → ? | kidney cancer | Mount Vernon Cancer Centre at Mount Vernon Hospital | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | recombinant interferon alpha-2a | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00873236 ↗ |
| Route | Subcutaneous | “recombinant interferon alpha-2a subcutaneously (SC)” NCT00873236 ↗ |